Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group
- Author:
Shinkyo YOON
1
;
Miso KIM
;
Yong Sang HONG
;
Han Sang KIM
;
Seung Tae KIM
;
Jihun KIM
;
Hongseok YUN
;
Changhoon YOO
;
Hee Kyung AHN
;
Hyo Song KIM
;
In Hee LEE
;
In-Ho KIM
;
Inkeun PARK
;
Jae Ho JEONG
;
Jaekyung CHEON
;
Jin Won KIM
;
Jina YUN
;
Sun Min LIM
;
Yongjun CHA
;
Se Jin JANG
;
Dae Young ZANG
;
Tae Won KIM
;
Jin Hyoung KANG
;
Jee Hyun KIM
Author Information
- Publication Type:Special Article
- From:Cancer Research and Treatment 2022;54(1):1-9
- CountryRepublic of Korea
- Language:English
- Abstract: Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea’s public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
